Rozga, Piotr <br/><br/>
Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance.  [electronic resource] 

 -  International journal of cancer  08 2020 
 - 1117-1130 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.32845  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>A549 Cells<br/>Animals<br/>Antineoplastic Agents--metabolism<br/>Apoptosis--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>HCT116 Cells<br/>HT29 Cells<br/>Hep G2 Cells<br/>Humans<br/>Mice, SCID<br/>Neoplasms--drug therapy<br/>Protein Engineering--methods<br/>Recombinant Fusion Proteins--genetics<br/>TNF-Related Apoptosis-Inducing Ligand--genetics<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays--methods